vaccination

Summary

Summary: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.

Top Publications

  1. pmc Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010
  2. pmc Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
    Troy D Querec
    Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, Georgia 30329, USA
    Nat Immunol 10:116-25. 2009
  3. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
  4. pmc Immunological mechanisms of vaccination
    Bali Pulendran
    Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:509-17. 2011
  5. pmc Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
  6. pmc Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites
    Noah S Butler
    Department of Microbiology, University of Iowa, 3 512 Bowen Science Building, Iowa City, IA 52242, USA
    Cell Host Microbe 9:451-62. 2011
  7. doi Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
    Eric Plennevaux
    Clinical Development Department, Sanofi Pasteur, Lyon, France
    Lancet 375:41-8. 2010
  8. ncbi Antibody response to influenza vaccination in the elderly: a quantitative review
    Katherine Goodwin
    National Institutes of Allergy and Infectious Diseases, Office of Global Affairs, 6610 Rockledge Drive, Room 2033, Bethesda, MD 20818, USA
    Vaccine 24:1159-69. 2006
  9. pmc Systems biology of vaccination for seasonal influenza in humans
    Helder I Nakaya
    Emory Vaccine Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:786-95. 2011
  10. doi Induction of broadly neutralizing H1N1 influenza antibodies by vaccination
    Chih Jen Wei
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892 3005, USA
    Science 329:1060-4. 2010

Detail Information

Publications333 found, 100 shown here

  1. pmc Induction of immunity to human immunodeficiency virus type-1 by vaccination
    M Juliana McElrath
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109, USA
    Immunity 33:542-54. 2010
    ....
  2. pmc Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
    Troy D Querec
    Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, Georgia 30329, USA
    Nat Immunol 10:116-25. 2009
    ..b>Vaccination induced genes that regulate virus innate sensing and type I interferon production...
  3. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  4. pmc Immunological mechanisms of vaccination
    Bali Pulendran
    Emory Vaccine Center at Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:509-17. 2011
    ..Here we will discuss these advances and emerging themes on the immunology of vaccination.
  5. pmc Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
    ..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1...
  6. pmc Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites
    Noah S Butler
    Department of Microbiology, University of Iowa, 3 512 Bowen Science Building, Iowa City, IA 52242, USA
    Cell Host Microbe 9:451-62. 2011
    ....
  7. doi Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials
    Eric Plennevaux
    Clinical Development Department, Sanofi Pasteur, Lyon, France
    Lancet 375:41-8. 2010
    ..from large clinical trials of paediatric, adult, and elderly people to find the appropriate antigen dose and vaccination schedule for the 2009 pandemic influenza A H1N1...
  8. ncbi Antibody response to influenza vaccination in the elderly: a quantitative review
    Katherine Goodwin
    National Institutes of Allergy and Infectious Diseases, Office of Global Affairs, 6610 Rockledge Drive, Room 2033, Bethesda, MD 20818, USA
    Vaccine 24:1159-69. 2006
    ..We conclude that the antibody response in the elderly is considerably lower than in younger adults. This highlights the need for more immunogenic vaccine formulations for the elderly...
  9. pmc Systems biology of vaccination for seasonal influenza in humans
    Helder I Nakaya
    Emory Vaccine Center, Emory University, Atlanta, Georgia, USA
    Nat Immunol 12:786-95. 2011
    Here we have used a systems biology approach to study innate and adaptive responses to vaccination against influenza in humans during three consecutive influenza seasons...
  10. doi Induction of broadly neutralizing H1N1 influenza antibodies by vaccination
    Chih Jen Wei
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, Bethesda, MD 20892 3005, USA
    Science 329:1060-4. 2010
    ..Here, we show that vaccination with plasmid DNA encoding H1N1 influenza hemagglutinin (HA) and boosting with seasonal vaccine or replication-..
  11. doi Optimizing influenza vaccine distribution
    Jan Medlock
    Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06520 8034, USA
    Science 325:1705-8. 2009
    ..We find that optimal vaccination is achieved by prioritization of schoolchildren and adults aged 30 to 39 years...
  12. ncbi A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
    D Morgan
    Department of Pharmacology, University of South Florida, Tampa 33612, USA
    Nature 408:982-5. 2000
    ..if the vaccinations had deleterious or beneficial functional consequences, we tested eight months of A beta vaccination in a different transgenic model for Alzheimer's disease in which mice develop learning deficits as amyloid ..
  13. ncbi Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
    Basil Donovan
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia
    Lancet Infect Dis 11:39-44. 2011
    ..From July, 2007, Australia was the first country to fund a vaccination programme for all women aged 12-26 years...
  14. pmc Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands
    Judith Spijkerman
    University Medical Center, Utrecht, The Netherlands
    Emerg Infect Dis 17:584-91. 2011
    ..PCV7 serotypes were largely replaced by non-PCV7 serotypes. Disappearance of PCV7 serotypes in parents suggests strong transmission reduction through vaccination.
  15. doi Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule
    Jim P Buttery
    Department of General Medicine and Murdoch Children s Research Institute, Royal Children s Hospital Melbourne, Parkville, Victoria, Australia Paediatric Infectious Diseases Unit, Monash Children s Hospital, Department of Paediatrics, Monash University, Melbourne, Victoria
    Pediatr Infect Dis J 30:S25-9. 2011
    ..This allowed comparison of both vaccines in similar populations with high infant vaccination coverage.
  16. pmc Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1
    Stephen Mark Tompkins
    Food and Drug Administration, Bethesda, Maryland, USA
    Emerg Infect Dis 13:426-35. 2007
    ..This vaccination induced antibodies that cross-reacted with divergent M2 peptide from an H5N1 subtype...
  17. doi HPV vaccine acceptability in Ghana, West Africa
    Maame Aba Coleman
    Baylor College of Medicine, Department of Obstetrics and Gynecology, Houston, TX 77030, USA
    Vaccine 29:3945-50. 2011
    Cervical cancer is a leading cause of cancer-related mortality among women in Ghana. As of this writing no data are available concerning knowledge, attitudes and acceptability of human papillomavirus (HPV) vaccination by women in Ghana.
  18. doi Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
    Nubia Munoz
    National Institute of Cancer, Bogota, Colombia
    Lancet 373:1949-57. 2009
    ..We tested the safety, immunogenicity, and efficacy of the quadrivalent HPV (types 6, 11, 16, 18) L1 virus-like-particle vaccine in women aged 24-45 years...
  19. ncbi Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong
    Benjamin J Cowling
    Infectious Disease Epidemiology Group, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
    Clin Infect Dis 51:1370-9. 2010
    ..The relationship between seasonal influenza vaccine and susceptibility to 2009 pandemic A/H1N1 virus infection is not fully understood...
  20. pmc Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study
    Stefan Flasche
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS Med 8:e1001017. 2011
    ....
  21. pmc Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
    Denis Gaucher
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal CR CHUM Saint Luc, Montreal, Quebec, Canada
    J Exp Med 205:3119-31. 2008
    ..to the yellow fever (YF) vaccine 17D (YF17D) in a cohort of 40 volunteers followed for up to 1 yr after vaccination. We show that immunization with YF17D leads to an integrated immune response that includes several effector ..
  22. doi Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
    Xiao Feng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Lancet 375:56-66. 2010
    ..The current influenza pandemic calls for a safe and effective vaccine. We assessed the safety and immunogenicity of eight formulations of 2009 pandemic influenza A H1N1 vaccine produced by ten Chinese manufacturers...
  23. ncbi Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
    Anthony E Fiore
    Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA 30333, USA
    MMWR Recomm Rep 58:1-52. 2009
    ..MMWR 2008;57[No. RR-7]). Information on vaccination issues related to the recently identified novel influenza A H1N1 virus will be published later in 2009...
  24. pmc Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
    Jens Wrammert
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nature 453:667-71. 2008
    ..Here we report that after booster vaccination there was a rapid and robust influenza-specific IgG+ antibody-secreting plasma cell (ASC) response that peaked ..
  25. pmc Current status of vaccines for schistosomiasis
    Donald P McManus
    Molecular Parasitology Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Brisbane Q4006, Australia
    Clin Microbiol Rev 21:225-42. 2008
    ..haematobium) and Asian (S. japonicum) schistosomes is then discussed, as are new approaches that may improve the efficacy of available vaccines and aid in the identification of new targets for immune attack...
  26. doi The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme
    Tim R H Read
    Department of Public Health, Melbourne Sexual Health Centre, Alfred Hospital and School of Population Health, University of Melbourne, Carlton, Victoria, Australia
    Sex Transm Infect 87:544-7. 2011
    ..Australia provided free quadrivalent human papillomavirus vaccines to 12-18-year-old girls and women aged ≤26 years from mid-2007 until the end of 2009. After this time, only girls aged 12-13 years had access to free vaccines...
  27. pmc Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic
    Danuta M Skowronski
    BC Centre for Disease Control, Vancouver, BC
    CMAJ 182:1851-6. 2010
    ..We reassessed this profile of seroprotection by age in the same region six months after the fall 2009 pandemic and vaccination campaign.
  28. pmc Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
    Viggo F Van Tendeloo
    University of Antwerp, Faculty of Medicine, Vaccine and Infectious Disease Institute Vaxinfectio and Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp B 2650, Belgium
    Proc Natl Acad Sci U S A 107:13824-9. 2010
    ..Here, in a phase I/II trial, we investigated the effect of autologous dendritic cell vaccination in 10 patients with acute myeloid leukemia (AML)...
  29. ncbi Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
    ..Such vectored vaccination regimes represent one of only two approaches that have induced repeatable partial efficacy in human P...
  30. ncbi Factors associated with uptake of vaccination against pandemic influenza: a systematic review
    Alison Bish
    Department of Clinical, Educational and Health Psychology, University College London, 1 19 Torrington Place, London WC1E 7HB, UK
    Vaccine 29:6472-84. 2011
    In June 2009 a global influenza pandemic was declared by the World Health Organisation. A vaccination programme against H1N1 influenza was introduced in many countries from September 2009, but there was low uptake in both the general ..
  31. doi Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation
    Marc Baguelin
    Centre for Infections, Health Protection Agency, United Kingdom
    Vaccine 28:2370-84. 2010
    ..We present a real-time assessment of the effectiveness and cost-effectiveness of alternative influenza A/H1N1v vaccination strategies...
  32. pmc HIV vaccines: lessons learned and the way forward
    Jerome H Kim
    Walter Reed Army Institute of Research, U S Military HIV Research Program, Rockville, Maryland, USA
    Curr Opin HIV AIDS 5:428-34. 2010
    ..An effective HIV vaccine is a global health priority. We describe lessons learned from four HIV vaccine trials that failed to demonstrate efficacy and one that showed modest protection as a pathway forward...
  33. pmc In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
    Laura C Bonifaz
    Laboratory of Cellular Physiology and Immunology, Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 199:815-24. 2004
    ..the immunizing functions of maturing dendritic cells, antibody-mediated antigen targeting via the DEC-205 receptor increases the efficiency of vaccination for T cell immunity, including systemic and mucosal resistance in disease models.
  34. doi Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial
    Zoltan Vajo
    University of Debrecen, Medical and Health Sciences Centre, Debrecen, Hungary
    Lancet 375:49-55. 2010
    ..We investigated the safety and immunogenicity of a whole-virion, inactivated, adjuvanted pandemic H1N1 vaccine in adult and elderly volunteers, given without or simultaneously with the 2009-10 seasonal trivalent influenza vaccine...
  35. pmc Heterologous prime-boost vaccination
    Shan Lu
    China US Vaccine Research Center and Department of Infectious Diseases, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China
    Curr Opin Immunol 21:346-51. 2009
    ..Heterologous prime-boost represents a new way of immunization and will stimulate better understanding on the immunological basis of vaccines...
  36. pmc Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870
    Vega Masignani
    IRIS, Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
    J Exp Med 197:789-99. 2003
    ..B meningococcus are devastating diseases of infants and young adults, which cannot yet be prevented by vaccination. By genome mining, we discovered GNA1870, a new surface-exposed lipoprotein of Neisseria meningitidis that ..
  37. doi Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data
    Andrew Clark
    Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 373:1543-9. 2009
    ..We estimated vaccination coverage at different ages, and delays in administration, in 45 low-income and middle-income countries.
  38. ncbi Pathogenesis of chronic Chagas heart disease
    Jose Antonio Marin-Neto
    Cardiology Division, Department of Internal Medicine, Medical School of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil
    Circulation 115:1109-23. 2007
    ..Despite nearly 1 century of research, the pathogenesis of chronic Chagas cardiomyopathy is incompletely understood, the most intriguing challenge of which is the complex host-parasite interaction...
  39. doi Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States
    Ben A Lopman
    Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 204:980-6. 2011
    Following the introduction of rotavirus vaccination in the United States, rotavirus and cause-unspecified gastroenteritis discharges significantly decreased in 2008 in the 0-4, 5-14, and 15-24-year age groups, with significant reductions ..
  40. doi Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China
    Fang Han
    Department of Pulmonary Medicine, Beijing University People s Hospital, Beijing, China
    Ann Neurol 70:410-7. 2011
    ..Recently, concern has been raised over reports of narcolepsy in northern Europe following H1N1 vaccination.
  41. doi Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to innovate intradermal vaccination design
    M B M Teunissen
    Department of Dermatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Curr Top Microbiol Immunol 351:25-76. 2012
    ..The skin is an attractive site for vaccination given the extended local network of DCs and the easy access to the skin-draining lymph nodes to generate ..
  42. pmc Vaccination and the theory of games
    Chris T Bauch
    Department of Mathematics and Statistics, University of Guelph, Guelph, ON, Canada N1G 2W1
    Proc Natl Acad Sci U S A 101:13391-4. 2004
    Voluntary vaccination policies for childhood diseases present parents with a subtle challenge: if a sufficient proportion of the population is already immune, either naturally or by vaccination, then even the slightest risk associated ..
  43. pmc Economic evaluation of human papillomavirus vaccination in the United Kingdom
    Mark Jit
    Modelling and Economics Unit, Centre for Infections, Health Protection Agency, London NW9 6BT
    BMJ 337:a769. 2008
    To assess the cost effectiveness of routine vaccination of 12 year old schoolgirls against human papillomavirus infection in the United Kingdom.
  44. doi Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign
    Angie Bone
    Institut de veille sanitaire French Institute for Public Health Surveillance, 12 Rue du Val d Osne, 94415 Saint Maurice Cedex, France
    Vaccine 28:8157-61. 2010
    A mass vaccination campaign against influenza A/H1N1 was launched in France in October 2009. Vaccination was offered free of charge to the entire population according to a pre-defined order of priority...
  45. doi Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas
    Clarisa B Palatnik-de-Sousa
    Department of General Microbiology, Institute of Microbiology Prof Paulo de Góes, Federal University of Rio de Janeiro UFRJ, Rio de Janeiro, RJ, Brazil
    Vaccine 27:3505-12. 2009
    ..We demonstrate here that vaccination with Leishmune does not interfere with the serological control campaign (110,000 dogs). Only 1...
  46. doi Future vaccination strategies against tuberculosis: thinking outside the box
    Stefan H E Kaufmann
    Department of Immunology, Max Planck Institute for Infection Biology, Chariteplatz 1, D 10117 Berlin, Germany
    Immunity 33:567-77. 2010
    ..Here, we review current and future strategies toward the rational design of novel vaccines against TB, as well as the progress made thus far, and the hurdles that need to be overcome in the near and distant future...
  47. doi Global status of Haemophilus influenzae type b and pneumococcal conjugate vaccines: evidence, policies, and introductions
    Orin S Levine
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, International Vaccine Access Center, Baltimore, Maryland, USA
    Curr Opin Infect Dis 23:236-41. 2010
    ..This study reviews the status of vaccine use globally and the evidence base that supports policy recommendations for use of these vaccines in children...
  48. doi The aging of the immune system
    Daniela Weiskopf
    Immunology Division, Institute for Biomedical Aging Research, Innsbruck, Austria
    Transpl Int 22:1041-50. 2009
    ..partially responsible for the increased prevalence and severity of infectious diseases, and the low efficacy of vaccination in elderly persons...
  49. ncbi Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae
    Katherine L O'Brien
    Pediatr Infect Dis J 22:e1-11. 2003
    ..Numerous studies evaluating the efficacy of conjugate pneumococcal vaccines are being conducted or planned throughout the world. Some of these studies are evaluating the effect of vaccine on nasopharyngeal (NP) carriage...
  50. pmc Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination
    Bruna C G de Alencar
    Centro Interdisciplinar de Terapia Gênica CINTERGEN, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo, SP 04044 010, Brazil
    Infect Immun 77:4383-95. 2009
    ..Our study thus demonstrated a role for perforin and IFN-gamma in a number of T-cell-mediated effector functions and in the antiparasitic immunity generated by a heterologous plasmid DNA prime-adenovirus boost vaccination strategy.
  51. ncbi Vaccines and vaccination strategies against human cutaneous leishmaniasis
    Ifeoma Okwor
    Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, CA
    Hum Vaccin 5:291-301. 2009
    ..However, there is as yet no effective vaccine against the disease in humans. Although vaccination in murine studies has yielded promising results, these vaccines have failed miserably when tested in primates ..
  52. ncbi Tutorial in biostatistics: the self-controlled case series method
    Heather J Whitaker
    Department of Statistics, The Open University, Milton Keynes, MK7 6AA, UK
    Stat Med 25:1768-97. 2006
    ..Some brief pointers on the design of case series studies are provided. The data sets, STATA code, and further implementation details in SAS, GENSTAT and GLIM are available from an associated website...
  53. pmc Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance
    Mark W Lamere
    Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Virol 85:5027-35. 2011
    ..The high conservation of NP antigen and the known longevity of antibody responses suggest that the antiviral activity of anti-NP IgG may provide a critically needed component of a universal influenza vaccine...
  54. ncbi Tularemia as a biological weapon: medical and public health management
    D T Dennis
    Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, PO Box 2087, Fort Collins, CO 80522, USA
    JAMA 285:2763-73. 2001
    ..The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals if tularemia is used as a biological weapon against a civilian population...
  55. ncbi Haemophilus influenzae: a significant pathogen in acute otitis media
    Eugene Leibovitz
    Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    Pediatr Infect Dis J 23:1142-52. 2004
    ..influenzae from the middle ear space. In the United States, widespread pneumococcal vaccination has increased the importance of H. influenzae as a major therapeutic challenge in the treatment of AOM.
  56. pmc Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: a longitudinal study
    Qiuyan Liao
    Health Behaviours Research Group, Department of Community Medicine and School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China
    PLoS ONE 6:e17713. 2011
    b>Vaccination was a core component for mitigating the 2009 influenza pandemic (pH1N1). However, a vaccination program's efficacy largely depends on population compliance...
  57. doi The cost-effectiveness of male HPV vaccination in the United States
    Harrell W Chesson
    National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Vaccine 29:8443-50. 2011
    The objective of this study was to estimate the cost-effectiveness of adding human papillomavirus (HPV) vaccination of 12-year-old males to a female-only vaccination program for ages 12-26 years in the United States.
  58. pmc DNA vaccination with a gene encoding Toxoplasma gondii GRA6 induces partial protection against toxoplasmosis in BALB/c mice
    Xi Meng Sun
    National Animal Protozoa Laboratory and College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
    Parasit Vectors 4:213. 2011
    ..gondii infected BALB/c mice with an H-2Ld gene. The CD8+ T cell response of H-2Ld mice infected by the T. gondii strain seemed to target entirely to a single GRA6 peptide HF10-H-2Ld complex...
  59. pmc The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens
    Carmen Elena Gómez
    Centro Nacional de Biotecnologia, CSIC, Madrid 28049, Spain
    J Virol 85:11468-78. 2011
    ..proportion of responders after two doses of MVA-B was similar to that obtained after the third dose of MVA-B vaccination, and the responses were sustained (84.6% at week 48)...
  60. pmc 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?
    Yoon Hong Choi
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e26190. 2011
    The UK introduced the 7-valent pneumococcal conjugate vaccine (PCV7) into the national vaccination program in September 2006...
  61. pmc Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs
    José E Aparicio-Burgos
    Centro de Investigacion y Estudios Avanzados, Universidad Autónoma de Estado de México, Toluca, Mexico
    PLoS Negl Trop Dis 5:e1050. 2011
    ..Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States...
  62. pmc BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
    Laurent Derre
    Ludwig Institute for Cancer Research, Hopital Orthopedique, Niveau 5 Est, Av Pierre Decker 4, Lausanne, Switzerland
    J Clin Invest 120:157-67. 2010
    ..CD8+ T cells from melanoma patients with spontaneous antitumor immune responses and after conventional peptide vaccination. Remarkably, addition of CpG oligodeoxynucleotides to the vaccine formulation led to progressive downregulation ..
  63. pmc Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland
    Markku Partinen
    Helsinki Sleep Clinic, Vitalmed Research Centre, Helsinki, Finland
    PLoS ONE 7:e33723. 2012
    ..Therefore, we carried out a systematic analysis of the incidence of narcolepsy in Finland between the years 2002-2010...
  64. pmc Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria
    Ally Olotu
    Kenya Medical Research Institute Wellcome Trust Programme, Centre for Geographic Medicine Research, Coast, Kilifi, Kenya
    PLoS ONE 6:e25786. 2011
    ..falciparum. We studied CS-specific T cell responses in order to identify correlates of protection...
  65. doi Rotavirus vaccines in Belgium: policy and impact
    Tessa Braeckman
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
    Pediatr Infect Dis J 30:S21-4. 2011
    The current Belgian experience with rotavirus vaccination provides a unique perspective to look at the effect of vaccination...
  66. doi AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age
    Francois Roman
    GlaxoSmithKline Biologicals, Wavre
    Clin Infect Dis 51:668-77. 2010
    b>Vaccination of high-risk groups was started shortly after the emergence of the influenza A (H1N1)2009 pandemic virus.
  67. doi Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 29:9127-31. 2011
    ..Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for 2 doses under a year was 78% (95% confidence interval -18% to 96%) and 77% (38-91%) for one dose ..
  68. pmc Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden
    Carola Bardage
    Medical Products Agency, PO Box 26, SE 751 03 Uppsala, Sweden
    BMJ 343:d5956. 2011
    ..To examine the risk of neurological and autoimmune disorders of special interest in people vaccinated against pandemic influenza A (H1N1) with Pandemrix (GlaxoSmithKline, Middlesex, UK) compared with unvaccinated people over 8-10 months...
  69. pmc A general approach for population games with application to vaccination
    Timothy C Reluga
    Department of Mathematics, Pennsylvania State University, State College, PA 16802, USA
    Math Biosci 230:67-78. 2011
    ..To illustrate our technique, we provide solutions to several variants of the simple vaccination game including imperfect vaccine efficacy and differential waning of natural and vaccine immunity...
  70. pmc High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model
    Sheetij Dutta
    Department of Epitope Mapping, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
    PLoS ONE 4:e8138. 2009
    ..High titers of cross-strain inhibitory antibodies against AMA1 are therefore critical to confer solid protection, and the Aotus model can be used to down-select future AMA1 formulations, prior to advanced human trials...
  71. doi Viruses as vaccine vectors for infectious diseases and cancer
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford, OX3 7DQ, UK
    Nat Rev Microbiol 8:62-73. 2010
    ....
  72. pmc Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    Andrew T Catanzaro
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3017, USA
    J Infect Dis 194:1638-49. 2006
    ..Here, we report the safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine...
  73. pmc Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus
    Hiroyuki Kayamuro
    Laboratory of Biopharmaceutical Research, National Institute of Biomedical Innovation, 7 6 8 Saito Asagi, Ibaraki, Osaka 567 0085, Japan
    J Virol 84:12703-12. 2010
    ..In summary, our results demonstrate that IL-1 family cytokines are potential mucosal vaccine adjuvants and can induce Ag-specific immune responses for protection against pathogens like influenza virus...
  74. ncbi Influenza vaccine coverage rates and perceptions on vaccination in South Korea
    Sae Yoon Kee
    Division of Infectious Diseases, Department of Internal Medicine, Korea University Medical College, 97 Gurodonggil, Gurodong, Gurogu, Seoul, Republic of Korea
    J Infect 55:273-81. 2007
    This survey was performed to assess the level of influenza vaccine coverage, to understand the driving forces and barriers to vaccination and determine vaccination interventions for the following year in Korean population.
  75. ncbi Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1
    Robert M Paris
    US Military HIV Research Program MHRP, Department of Retrovirology, Armed Forces Research Institute of Medical Sciences, 315 6 Rajvithi Road, Bangkok, 10400, Thailand
    Expert Rev Vaccines 9:1055-69. 2010
    ....
  76. doi Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination
    Victoria R Polonis
    Walter Reed Army Institute of Research, Washington, DC, USA
    Virology 375:315-20. 2008
    ....
  77. pmc Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi
    Paula Ordonhez Rigato
    CTCMol, UNIFESP, Escola Paulista de Medicina, Rua Mirassol 207, Sao Paulo, SP, Brazil 04044 010
    Infect Immun 79:2120-30. 2011
    ..From these results, we concluded that heterologous plasmid DNA prime-adenovirus boost vaccination generated a stable pool of functional protective long-lived CD8(+) T cells with an effector memory phenotype.
  78. ncbi Blood-stage malaria vaccines - recent progress and future challenges
    A L Goodman
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
    Ann Trop Med Parasitol 104:189-211. 2010
    ..The future challenges that face this field of vaccine research are also described...
  79. ncbi Influenza vaccination and mortality benefits: new insights, new opportunities
    Lone Simonsen
    Department of Global Health, School of Public Health and Health Services, George Washington University, Washington, DC 20818, USA
    Vaccine 27:6300-4. 2009
    Influenza vaccination control strategies in most countries rely on vaccination of seniors and other high risk groups...
  80. pmc Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1
    Adel Benlahrech
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    Proc Natl Acad Sci U S A 106:19940-5. 2009
    ..individuals that were seropositive for adenovirus serotype 5 (Ad5) showed increased rates of HIV-1 infection on vaccination with an Ad5 vaccine...
  81. pmc Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis
    P C Melby
    Medical Service, Department of Veterans Affairs Medical Center, South Texas Veterans Health Care System, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Infect Immun 69:4719-25. 2001
    ..following subclinical or resolved infection with the intracellular parasite Leishmania donovani suggests that vaccination could prevent visceral leishmaniasis (VL)...
  82. ncbi Challenges and perspectives in vaccination against leishmaniasis
    Camila I de Oliveira
    Centro de Pesquisas Gonçalo Muniz FIOCRUZ, Salvador, BA, Brazil
    Parasitol Int 58:319-24. 2009
    ..issues that have been poorly addressed in ongoing efforts to develop a vaccine against Leishmania, namely: vaccination with antigens present in sand fly saliva, vaccines based on intracellular Leishmania antigens, and use of ..
  83. pmc Vaccination strategies to promote mucosal antibody responses
    Kang Chen
    Department of Medicine, Immunology Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Immunity 33:479-91. 2010
    ..We review the important cellular interactions and molecular pathways underlying the induction and regulation of mucosal antibody responses and discuss their implications on mucosal vaccination.
  84. pmc Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model
    Wentao Jia
    Department of Neurosurgery, Virginia Commonwealth, Richmond, VA 23298 0631, USA
    J Neuroimmunol 223:20-30. 2010
    ..These findings suggest that neuro-immunomodulation by MDSC in rat gliomas maybe mediated by a pathway requiring NO production...
  85. pmc Vaccination in the elderly: an immunological perspective
    Wilbur H Chen
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Trends Immunol 30:351-9. 2009
    Successful vaccination of the elderly against important infectious pathogens that cause high morbidity and mortality represents a growing public health priority...
  86. pmc Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate
    Jeffrey R Currier
    United States Military HIV Research Program, Rockville, Maryland, United States of America
    PLoS ONE 5:e13983. 2010
    ..The HIV sequences were derived from circulating recombinant form CRF01_AE, which predominates in Thailand. The objective was to evaluate safety and immunogenicity of MVA-CMDR in human volunteers in the US and Thailand...
  87. pmc Economic value of seasonal and pandemic influenza vaccination during pregnancy
    Richard H Beigi
    Division of Reproductive Infectious Diseases, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA
    Clin Infect Dis 49:1784-92. 2009
    ..The study objective was to evaluate the cost-effectiveness of maternal influenza vaccination using both single- and 2-dose strategies against laboratory-confirmed influenza secondary to both seasonal ..
  88. pmc High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma
    Jochen Greiner
    Department of Internal Medicine III, University of Ulm, Albert Einstein Allee 23 89081 Ulm, Germany
    Haematologica 95:1191-7. 2010
    ..To improve the outcome of the vaccine, a second cohort was vaccinated with a higher dose of 1,000 microg peptide...
  89. pmc Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination
    Stephanie A Freel
    Duke University Human Vaccine Institute, Departments of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Virol 84:4998-5006. 2010
    Control of HIV-1 replication following nonsterilizing HIV-1 vaccination could be achieved by vaccine-elicited CD8(+) T-cell-mediated antiviral activity...
  90. doi Harnessing invariant NKT cells in vaccination strategies
    Vincenzo Cerundolo
    Tumour Immunology Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DU, UK
    Nat Rev Immunol 9:28-38. 2009
    To optimize vaccination strategies, it is important to use protocols that can 'jump-start' immune responses by harnessing cells of the innate immune system to assist the expansion of antigen-specific B and T cells...
  91. pmc Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis
    Diane Ordway
    Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523 1682, USA
    Clin Vaccine Immunol 15:1248-58. 2008
    ..Whereas BCG vaccination reduced the influx of heterophils (neutrophils) into the lungs, an early B-cell influx was observed in these ..
  92. pmc Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma
    H Schori
    Department of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, Israel
    Proc Natl Acad Sci U S A 98:3398-403. 2001
    ....
  93. pmc Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis
    Andrea Cruz
    Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710 057 Braga, Portugal
    J Exp Med 207:1609-16. 2010
    ..a model wherein mice are vaccinated with bacille Calmette-Guérin after Mtb infection, we show that repeated vaccination results in increased IL-17, tumor necrosis factor, IL-6, and MIP-2 expression, influx of granulocytes/..
  94. ncbi Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein
    Robert Strauss
    Department of Medicine, Division of Medical Genetics, University of Washington, Seattle, Washington, USA
    Mol Ther 15:193-202. 2007
    ..In this study, we evaluated the potential of baculovirus vectors for malaria vaccination. To induce efficient CD4(+) and CD8(+) T-cell responses, we produced a series of vectors that display the ..
  95. ncbi Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model
    Akihiro Mouri
    Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsuruma cho, Showa Ku, Nagoya 466 8560, Japan
    FASEB J 21:2135-48. 2007
    ..Taken together, these results suggest that immunotherapy with AAV/Abeta is a safe and effective treatment for AD...
  96. doi Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among hospital staff in a medical center in Taiwan
    Yu Jiun Chan
    Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
    J Chin Med Assoc 73:62-6. 2010
    ..In addition to specific antiviral agents, massive vaccination is thought to be the most effective way of controlling the transmission...
  97. ncbi Proteome-wide analysis of the serological response to vaccinia and smallpox
    D Huw Davies
    Center for Virus Research, University of California, Irvine, CA 92697, USA
    Proteomics 7:1678-86. 2007
    The eradication of smallpox by vaccination with vaccinia virus was probably one of the greatest achievements of vaccinology. However, the immunological basis of this protection is not fully understood...
  98. ncbi A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles
    Pratip K Chattopadhyay
    Immunotechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, 40 Convent Drive, Room 5509, Bethesda, Maryland 20892, USA
    Nat Med 11:1113-7. 2005
    ..For vaccine- or pathogen-specific responses, we found substantial heterogeneity in expression of CD154 and cytokines, suggesting previously unrecognized diversity in abilities of responding cells to stimulate APCs through CD40...
  99. ncbi Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches
    Sun Young Kim
    Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    Pharmacoeconomics 26:191-215. 2008
    ..effectiveness, taking into account the relevant biological, clinical, epidemiological and economic factors of a vaccination programme, generally requires use of a model...
  100. pmc Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles
    Jae Min Song
    Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA
    Antiviral Res 88:244-7. 2010
    To develop a more effective vaccination method against H5N1 virus, we investigated the immunogenicity and protective efficacy after skin vaccination using microneedles coated with influenza virus-like particles containing hemagglutinin ..
  101. doi Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age
    Sarah Burl
    Medical Research Council United Kingdom, The Gambia, Fajara, The Gambia, West Africa
    J Immunol 185:2620-8. 2010
    ..Gambian neonates were recruited at birth and randomized to receive BCG vaccination either at birth or at 4 1/2 mo. Mycobacterial immune responses were assessed at birth, 4 1/2, and 9 mo of age...

Research Grants103 found, 100 shown here

  1. Modulation of Biodefense Responses to Microbial Pathogens
    Leo Lefrancois; Fiscal Year: 2009
    ..strains will continue to cause human that new strains will continue to cause human pandemics until efficient vaccination strategies can be developed. Antibodies and T cells are important be developed...
  2. Cellular Immunity to Category A-C Viruses in Humans
    Alan L Rothman; Fiscal Year: 2010
    ..PROJECT 1: Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination (TERAJIMA, M) PROJECT 1 The overall goal of this project is to define the human T-cell responses to influenza ..
  3. Cellular Immunity to Category A-C Viruses in Humans
    Alan L Rothman; Fiscal Year: 2010
    ..PROJECT 1: Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination (TERAJIMA, M) PROJECT 1 The overall goal of this project is to define the human T-cell responses to influenza ..
  4. Cellular Immunity to Category A-C Viruses in Humans
    Alan Rothman; Fiscal Year: 2009
    ..PROJECT 1: Human CD8+ and CD4+ T Cells Responses to Influenza Infection and Vaccination (TERAJIMA, M) PROJECT 1 The overall goal of this project is to define the human T-cell responses to influenza ..
  5. IDENTIFICATION OF SIV SPECIFIC T HELPER EPITOPES & THEIR RESTRICTING ALLELES
    MC GAUDUIN; Fiscal Year: 2000
    ..attenuated SIV to induce a strong, sustained type 1 T helper response may play a role in the success of this vaccination approach to generate protection against challenge with wild-type SIV Aldovini, A - Children's Hospital, Harvard ..
  6. VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
    Rafi Ahmed; Fiscal Year: 2009
    ..the cellular basis of immune senescence and develop strategies for improving responses of the elderly to vaccination. A major emphasis of this proposal was to use genomics to define molecular signatures of a successful vaccine, ..
  7. VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
    Rafi Ahmed; Fiscal Year: 2009
    ..the cellular basis of immune senescence and develop strategies for improving responses of the elderly to vaccination. A major emphasis of this proposal was to use genomics to define molecular signatures of a successful vaccine, ..
  8. VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
    Rafi Ahmed; Fiscal Year: 2010
    ..the cellular basis of immune senescence and develop strategies for improving responses of the elderly to vaccination. A major emphasis of this proposal was to use genomics to define molecular signatures of a successful vaccine, ..
  9. VACCINE INDUCED IMMUNITY IN THE YOUNG AND AGED
    Rafi Ahmed; Fiscal Year: 2009
    ..the cellular basis of immune senescence and develop strategies for improving responses of the elderly to vaccination. A major emphasis of this proposal was to use genomics to define molecular signatures of a successful vaccine, ..
  10. Mucosal Immunity and Influenza Vaccines: Phenotype and Role of Activated B Cells
    HARRY BERNARD GREENBERG; Fiscal Year: 2010
    ..a critical component of the influenza mucosal immunity, traditional analyses of B cell immunity after influenza vaccination have been largely limited to studies of serum antibodies, which do not provide adequate or unified markers for ..
  11. Role of cyclooxygenase-2 in antibody responses to vaccination
    Richard Phipps; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Optimal humoral (i.e. antibody) responses to vaccination are essential if humans are to be protected against potentially devastating infectious agents...
  12. VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS
    Liise Anne Pirofski; Fiscal Year: 2003
    ..This emergence of antibiotic resistant pneumococcus has increased the need for vaccination of high-risk groups such as HIV+ persons...
  13. VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS
    Liise Anne Pirofski; Fiscal Year: 2004
    ..This emergence of antibiotic resistant pneumococcus has increased the need for vaccination of high-risk groups such as HIV+ persons...
  14. VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS
    Liise Anne Pirofski; Fiscal Year: 2000
    ..This emergence of antibiotic resistant pneumococcus has increased the need for vaccination of high-risk groups such as HIV+ persons...
  15. VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS
    Liise Anne Pirofski; Fiscal Year: 2001
    ..This emergence of antibiotic resistant pneumococcus has increased the need for vaccination of high-risk groups such as HIV+ persons...
  16. VARIABLE GENE USE AND PNEUMOCOCCAL IMMUNITY IN AIDS
    Liise Anne Pirofski; Fiscal Year: 2002
    ..This emergence of antibiotic resistant pneumococcus has increased the need for vaccination of high-risk groups such as HIV+ persons...
  17. Statin modulation of immunotherapy for Alzheimer disease
    Jun Tan; Fiscal Year: 2009
    ..A different anti-AD strategy, vaccination with the A( peptide, also reduces A( deposition in AD transgenic mice and improves cognition...
  18. HPV Knowledge Awareness and Vaccine Acceptability among Inner City Black Males
    SHERRIE LEE WALLINGTON; Fiscal Year: 2012
    ..In 2009, the District of Columbia (DC) made HPV vaccination mandatory for all girls entering the 6th grade, with an opt-out option available by parental request...
  19. Transcriptional control of IL-7 receptor (IL-7R) in T cells
    SUSAN M contact KAECH; Fiscal Year: 2010
    ..S. (www.who.int/whosis/database). Vaccination offers the greatest hope for reducing the negative impact of infectious disease by generating long-lived ..
  20. Transcriptional control of IL-7 receptor (IL-7R) in T cells
    Susan Kaech; Fiscal Year: 2009
    ..S. (www.who.int/whosis/database). Vaccination offers the greatest hope for reducing the negative impact of infectious disease by generating long-lived ..
  21. Recommendation of HPV Vaccination among U.S. Physicians
    Susan Vadaparampil; Fiscal Year: 2009
    ..The ACIP recommendation also allows for vaccination of girls beginning at age nine as well as catch-up vaccination of girls and women 13-26 years of age...
  22. Recommendation of HPV Vaccination among U.S. Physicians
    Susan T Vadaparampil; Fiscal Year: 2010
    ..The ACIP recommendation also allows for vaccination of girls beginning at age nine as well as catch-up vaccination of girls and women 13-26 years of age...
  23. Vaccination and infection: indicators of immunological health and responsiveness
    MARK MORRIS DAVIS; Fiscal Year: 2010
    ..PROJECT 1 Title: Plasmablast Trafficking and Antibody Response in Influenza Infection and Vaccination Project Leader: Greenberg, H PROJECT 1 DESCRIPTION (provided by applicant): Plasmablast trafficking and ..
  24. Acceptability and feasbility of the HPV vaccine schedule in female sex workers
    Brandon Brown; Fiscal Year: 2009
    ..survey will be administered at baseline and upon follow-up at month 7 to collect information on barriers to vaccination and other relevant data including awareness of HPV, STI history, age, condom use, reported pregnancies, ..
  25. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2011
    ..advice from our community partners who have successfully treated parolees and our experience with hepatitis vaccination work, we propose to conduct a prospective, three-group study that randomly assigns 700 ready-for- discharge ..
  26. Anti-Idiotype Therapy of Human B Cell Malignancy
    Ronald Levy; Fiscal Year: 2007
    ..Animal models of B cell lymphoma will be used to develop more powerful methods of vaccination against the idiotype and to study the mechanisms of tumor immunity...
  27. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
    ..advice from our community partners who have successfully treated parolees and our experience with hepatitis vaccination work, we propose to conduct a prospective, three-group study that randomly assigns 700 ready-for- discharge ..
  28. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline M Nyamathi; Fiscal Year: 2010
    ..advice from our community partners who have successfully treated parolees and our experience with hepatitis vaccination work, we propose to conduct a prospective, three-group study that randomly assigns 700 ready-for- discharge ..
  29. Health Promotion Coaching/Vaccine for Homeless Parolees
    Adeline Nyamathi; Fiscal Year: 2009
    ..advice from our community partners who have successfully treated parolees and our experience with hepatitis vaccination work, we propose to conduct a prospective, three-group study that randomly assigns 700 ready-for- discharge ..
  30. Low cost molecular assay for HIV
    BERTRAND LEMIEUX; Fiscal Year: 2009
    ..applicant): We propose to develop a rapid, low cost, threshold assay for the detection of HIV infection of HIV vaccination trial participants...
  31. Evaluation of vaccination reminder/recall systems for adolescent patients
    Peter Szilagyi; Fiscal Year: 2009
    ..and recall adolescents for needed immunizations, particularly among low-income adolescents who have lower vaccination rates and fewer preventive healthcare visits...
  32. Improving the efficacy of anti-nicotine immunotherapy
    Alexey G Mukhin; Fiscal Year: 2010
    ..by applicant): The long-term goal of this research project is to improve the efficacy of anti-nicotine vaccination/immunotherapy for smoking cessation...
  33. Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate
    Charles P Rodi; Fiscal Year: 2010
    ..provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat infections associated with S. aureus/MRSA...
  34. Improving the efficacy of anti-nicotine immunotherapy
    ALEXEY MUKHIN; Fiscal Year: 2009
    ..by applicant): The long-term goal of this research project is to improve the efficacy of anti-nicotine vaccination/immunotherapy for smoking cessation...
  35. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2009
    ..HIFU would be used to ablate the local tumor and release tumor-derived HSPs and peptides for an in situ auto-vaccination. In a recently completed phase I SBIR proposal (PI, Naren Sanghvi, Focus Surgery), we demonstrated that cycles ..
  36. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2010
    ..HIFU would be used to ablate the local tumor and release tumor-derived HSPs and peptides for an in situ auto-vaccination. In a recently completed phase I SBIR proposal (PI, Naren Sanghvi, Focus Surgery), we demonstrated that cycles ..
  37. HIFU-enhanced tumor vaccines
    Chandan Guha; Fiscal Year: 2010
    ..HIFU would be used to ablate the local tumor and release tumor-derived HSPs and peptides for an in situ auto-vaccination. In a recently completed phase I SBIR proposal (PI, Naren Sanghvi, Focus Surgery), we demonstrated that cycles ..
  38. Predictors of Immunologic Failure in Older Adults
    DAVID CANADAY; Fiscal Year: 2009
    ..It has been established that increasing age leads to both immunologic dysfunction and poor responses to vaccination. The overall hypothesis that frailty and age predict immunologic and vaccination failure in older adults...
  39. Enhanced Surveillance for New Vaccine Preventable Diseases
    Rangaraj Selvarangan; Fiscal Year: 2011
    ..system can be effectively utilized to study the impact of new or upcoming vaccines and policies relating to vaccination. Our active surveillance system will monitor community rates of acute gastroenteritis (AGE) and acute ..
  40. Decision-Making about Childhood HPV Vaccination among Low SES Mothers
    TIFFANY FLOYD; Fiscal Year: 2009
    ..Given the necessity of parental consent for the vaccination of minors, as well as the enhanced efficacy of the vaccine when delivered prior to the onset of the sexual ..
  41. Systems Analysis Vaccine Responses in Healthy and Hyporesponsive Humans
    JACQUES F BANCHEREAU; Fiscal Year: 2010
    ..their shortcomings by studying hypo-responsive people will permit us to unravel the immunological principles of vaccination. Three vaccines will be studied in great detail: inactivated influenza vaccine and hepatitis B vaccine with ..
  42. A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200
    Warner Huh; Fiscal Year: 2009
    ..The two HPV capsid proteins, L1 and L2, are both independent protective antigens. Vaccination with HPV L1 virus-like particles (VLP) induces neutralizing antibodies and protection in patients with strong ..
  43. A Phase I Study to Evaluate the Safety and Immunogenicity of HPV 16 L2 11-200
    WARNER KING HUH; Fiscal Year: 2010
    ..The two HPV capsid proteins, L1 and L2, are both independent protective antigens. Vaccination with HPV L1 virus-like particles (VLP) induces neutralizing antibodies and protection in patients with strong ..
  44. MUCOSAL IMMUNITY TO HIV ENV BY ORAL VACCINATION
    Danuta Kozbor; Fiscal Year: 2001
    ..to explore the possibility of using poly(DL-lactide-co-glycolide) (PLG) microparticles as vehicles for oral vaccination with plasmid DNA encoding gp160 in combination with recombinant viral vectors expressing the env gene products ..
  45. MUCOSAL IMMUNITY TO HIV ENV BY ORAL VACCINATION
    Danuta Kozbor; Fiscal Year: 2001
    ..to explore the possibility of using poly(DL-lactide-co-glycolide) (PLG) microparticles as vehicles for oral vaccination with plasmid DNA encoding gp160 in combination with recombinant viral vectors expressing the env gene products ..
  46. Toward suicidal automation of porphyric Leishmania for photodynamic vaccination
    Kwang Poo Chang; Fiscal Year: 2010
    ..It is possible to increase the safety margin of live Leishmania for vaccination by molecular genetic approaches to attenuate their pathogenicity or to construct suicidal mutants...
  47. Toward suicidal automation of porphyric Leishmania for photodynamic vaccination
    Kwang Poo Chang; Fiscal Year: 2009
    ..It is possible to increase the safety margin of live Leishmania for vaccination by molecular genetic approaches to attenuate their pathogenicity or to construct suicidal mutants...
  48. MUCOSAL IMMUNITY TO HIV ENV BY ORAL VACCINATION
    Danuta Kozbor; Fiscal Year: 2000
    ..to explore the possibility of using poly(DL-lactide-co-glycolide) (PLG) microparticles as vehicles for oral vaccination with plasmid DNA encoding gp160 in combination with recombinant viral vectors expressing the env gene products ..
  49. The Role of CD1a in Protecting Against Human Tuberculosis
    Chetan Seshadri; Fiscal Year: 2010
    ..immediate goals are to study the role of lipid antigen presentation in the immunologic and clinical response to vaccination against tuberculosis...
  50. Innate immune regulation of inflammation and adaptive immunity
    Anthony DeFranco; Fiscal Year: 2009
    ..Nonetheless, much remains to be learned before we truly understand how to harness these mechanisms for vaccination and cancer immunotherapy or how to block them to treat autoimmune and inflammatory disease...
  51. TNF family members for lymph angiogenesis and lymph node hypertrophy
    Yang Xin Fu; Fiscal Year: 2010
    ..venules (HEV) in peripheral tissues leads to hypertrophy of draining lymph nodes (LN) during inflammation/vaccination, but the molecular mechanism regulating LN hypertrophy is poorly understood...
  52. Stable Micronized Vaccines Against Smallpox and Japanese Encephalitis
    VICTOR BRONSHTEIN; Fiscal Year: 2007
    ..the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained...
  53. Stable Micronized Vaccines Against Smallpox and Japanese Encephalitis
    VICTOR BRONSHTEIN; Fiscal Year: 2006
    ..the existence of variola stockpiles and the threat of bioterrorism demand that immunity to smallpox through vaccination be maintained...
  54. Defining signatures for immune responsiveness by functional systems immunology
    DAVID A contact HAFLER; Fiscal Year: 2010
    ..gene signatures and biological pathways that can distinguish between strong and weak immune responses to vaccination and that predict effective responses...
  55. Mechanisms of non-neutralizing antibody-mediated protection from influenza virus
    DENISE KAMINSKI; Fiscal Year: 2009
    ..S. per year. Humans can be protected by vaccination against seasonal influenza strains...
  56. Mechanisms of non-neutralizing antibody-mediated protection from influenza virus
    DENISE KAMINSKI; Fiscal Year: 2009
    ..S. per year. Humans can be protected by vaccination against seasonal influenza strains...
  57. Oral Vaccination for AIDS Prevention in Rhesus Macaques
    Anna Aldovini; Fiscal Year: 2010
    ..We have established vaccination regimens that stimulate mucosal responses with an SIV DNA vaccine, which consists of a single plasmid carrying ..
  58. Oral Vaccination for AIDS Prevention in Rhesus Macaques
    Anna Aldovini; Fiscal Year: 2009
    ..We have established vaccination regimens that stimulate mucosal responses with an SIV DNA vaccine, which consists of a single plasmid carrying ..
  59. Enhanced Surveillance for New Vaccine Preventable Diseases
    Rangaraj Selvarangan; Fiscal Year: 2012
    ..system can be effectively utilized to study the impact of new or upcoming vaccines and policies relating to vaccination. Our active surveillance system will monitor community rates of acute gastroenteritis (AGE) and acute ..
  60. Enhanced Surveillance for New Vaccine Preventable Diseases-Patient Protection-ACA
    Rangaraj Selvarangan; Fiscal Year: 2011
    ..system can be effectively utilized to study the impact of new or upcoming vaccines and policies relating to vaccination. Our active surveillance system will monitor community rates of acute gastroenteritis (AGE) and acute ..
  61. In-ovo vaccination/avian influenza/bird/human
    DE CHU TANG; Fiscal Year: 2009
    ..The hypothesis is that mass-vaccination of poultry against an outbreak of avian influenza reduces the dissemination of the virus to new flocks and ..
  62. School Mandates for Human Papillomavirus Vaccination: Use of an Agent-Based Model
    David Mendez; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Currently, 24 states are considering legislation that would "mandate" vaccination against human papillomavirus (HPV), a sexually transmitted disease that causes cervical cancer, for girls entering ..
  63. Optimization of Tumor Vaccines for the Aged
    Joseph Lustgarten; Fiscal Year: 2011
    ..Our preliminary results indicate that treatment with intratumoral injections of CpG-ODN plus peptide vaccination and depletion of Tregs induce an immune response that reject the primary tumors in 100% of young A2xneu mice ..
  64. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2007
    ..Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitis-related morbidity and mortality...
  65. SIV VACCINATION AS A MODEL FOR AIDS VACCINES
    Arsene Burny; Fiscal Year: 1993
    ..This program addresses the parameters of efficient vaccination of macaques with SIV antigens and contains the following topics: - development of a reliable challenge system ..
  66. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2005
    ..Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitis-related morbidity and mortality...
  67. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2006
    ..Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitis-related morbidity and mortality...
  68. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2004
    ..Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitis-related morbidity and mortality...
  69. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2005
    ..Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitis-related morbidity and mortality...
  70. HBV Prevention for Homeless At-Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2003
    ..Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitis-related morbidity and mortality...
  71. SIV VACCINATION AS A MODEL FOR AIDS VACCINES
    Arsene Burny; Fiscal Year: 1990
    ..This program addresses the parameters of efficient vaccination of macaques with SIV antigens and contains the following topics: - development of a reliable challenge system ..
  72. Antibody persistence after conjugate meningococcal group A vaccination in Mali
    NICOLE ELAINE BASTA; Fiscal Year: 2011
    ..vaccine, in Burkina Faso, Mali, and Niger in December 2010 was the first ever population-based, preventive mass-vaccination campaign against meningococcal meningitis in the meningitis belt and the first- ever nationwide use of this ..
  73. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..We hypothesize that post-transplant vaccination with HA1 or HA2 peptides in combination with GM-CSF in donor-recipient pairs that are HLA-identical, but ..
  74. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2003
    ..We hypothesize that post-transplant vaccination with HA1 or HA2 peptides in combination with GM-CSF in donor-recipient pairs that are HLA-identical, but ..
  75. Adjuvant-containing chimeric virus-like particles as improved influenza vaccines
    Fu Shi Quan; Fiscal Year: 2009
    ..DESCRIPTION (provided by applicant): Although the influenza vaccine has been used for over 60 years, the current vaccination strategy against influenza A and B viruses is vulnerable to the unanticipated emergence of epidemic strains ..
  76. Adjuvant-containing chimeric virus-like particles as improved influenza vaccines
    FU SHI contact QUAN; Fiscal Year: 2010
    ..DESCRIPTION (provided by applicant): Although the influenza vaccine has been used for over 60 years, the current vaccination strategy against influenza A and B viruses is vulnerable to the unanticipated emergence of epidemic strains ..
  77. Dendritic Cell Control of Skin Immunity
    Terri Laufer; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Vaccination against infectious diseases is a major tool for prevention of morbidity and mortality for both veterans and active-duty soldiers...
  78. Development of a novel vaccine against congenital cytomegalovirus infection
    CHRISTOPHER MORELLO; Fiscal Year: 2009
    ..cells specific for an immunodominant antigen are ineffective at limiting viral replication, we speculated that vaccination using these antigens may at best elicit immunity that is not significantly greater than that generated during ..
  79. Empirical space-time evaluation of priority groups for influenza control
    John Brownstein; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Vaccination against influenza is the mainstay of prevention efforts and was initially targeted at older individuals and those with high risk of complications...
  80. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    The classic paradigm for understanding the immunobiology of cutaneous vaccination is that antigen delivered with an adjuvant creates an inflammatory stimulus, which in turn induces epidermal Langerhans cells to mature and to migrate to ..
  81. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2009
    The classic paradigm for understanding the immunobiology of cutaneous vaccination is that antigen delivered with an adjuvant creates an inflammatory stimulus, which in turn induces epidermal Langerhans cells to mature and to migrate to ..
  82. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2009
    The classic paradigm for understanding the immunobiology of cutaneous vaccination is that antigen delivered with an adjuvant creates an inflammatory stimulus, which in turn induces epidermal Langerhans cells to mature and to migrate to ..
  83. Poxvirus adverse effects on cardiac cells and the heart
    Barbara Sherry; Fiscal Year: 2004
    ..bioterrorists may release smallpox virus in the United States, the government has implemented a multi-stage vaccination program...
  84. Poxvirus adverse effects on cardiac cells and the heart
    Barbara Sherry; Fiscal Year: 2005
    ..bioterrorists may release smallpox virus in the United States, the government has implemented a multi-stage vaccination program...
  85. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2009
    ..RO1 award has enabled us to implement a successful intervention designed to evaluate the effectiveness of a HBV vaccination intervention with homeless adults...
  86. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline Nyamathi; Fiscal Year: 2009
    ..RO1 award has enabled us to implement a successful intervention designed to evaluate the effectiveness of a HBV vaccination intervention with homeless adults...
  87. HBV Prevention for Homeless at Risk for HBV/HCV/HIV
    Adeline M Nyamathi; Fiscal Year: 2010
    ..RO1 award has enabled us to implement a successful intervention designed to evaluate the effectiveness of a HBV vaccination intervention with homeless adults...
  88. Risk Factors for Eczema Vaccinatum in Atopic Dermatitis
    Peter Elias; Fiscal Year: 2005
    ..that smallpox virus might be employed as a bioterrorism agent has led to an early implementation of a limited vaccination program...
  89. Risk Factors for Eczema Vaccinatum in Atopic Dermatitis
    Walter Holleran; Fiscal Year: 2009
    ..that smallpox virus might be employed as a bioterrorism agent has led to an early implementation of a limited vaccination program...
  90. Risk Factors for Eczema Vaccinatum in Atopic Dermatitis
    Walter Holleran; Fiscal Year: 2007
    ..that smallpox virus might be employed as a bioterrorism agent has led to an early implementation of a limited vaccination program...
  91. From Innovation to Solutions: Autodialers, Use of Early Autumn Physicals and Vac
    Richard K Zimmerman; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): In 2008, the CDC expanded the indications for influenza vaccination to encompass children ages 6 months through 18 years, dramatically increasing the number of eligible children...
  92. From Innovation to Solutions: Autodialers, Use of Early Autumn Physicals and Vac
    Richard K Zimmerman; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): In 2008, the CDC expanded the indications for influenza vaccination to encompass children ages 6 months through 18 years, dramatically increasing the number of eligible children...
  93. ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WITH STEM CELL QUALITIES
    Stanley Riddell; Fiscal Year: 2009
    ..T cells is a hallmark of the host response to acute and persistent viral infections and a major objective of vaccination for infectious diseases and cancer...
  94. ANALYSIS OF A NOVEL SUBSET OF HUMAN CD8+ MEMORY CELLS WITH STEM CELL QUALITIES
    Stanley R Riddell; Fiscal Year: 2010
    ..T cells is a hallmark of the host response to acute and persistent viral infections and a major objective of vaccination for infectious diseases and cancer...
  95. Development of Breast Cancer Vaccines
    Wei Zen Wei; Fiscal Year: 2010
    ..We will test the hypothesis that vaccination with Her-2-neu hybrid DNA vaccine will reject established tumors and prevent tumor metastasis...
  96. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad J Spellberg; Fiscal Year: 2010
    ..We have also found that: 1) antibody titers d Als3p (rAls3p-N). We have found that vaccination of mice with r a vaccine to prevent life threatening Candida i Furthermore, infections caused by strains and ..
  97. Evaluation of vaccination reminder/recall systems for adolescent patients
    Allison Kempe; Fiscal Year: 2009
    ..provided by applicant): Although patient reminder/recall systems have been shown to be effective at improving vaccination coverage levels for infants and younger children, little is known about the effectiveness of such systems for ..
  98. Evaluation of vaccination reminder/recall systems for adolescent patients
    Allison Kempe; Fiscal Year: 2007
    ..provided by applicant): Although patient reminder/recall systems have been shown to be effective at improving vaccination coverage levels for infants and younger children, little is known about the effectiveness of such systems for ..
  99. Innate Effectors of rAls3p-N Anti-Candida Vaccine
    Brad Spellberg; Fiscal Year: 2009
    ..We have also found that: 1) antibody titers d Als3p (rAls3p-N). We have found that vaccination of mice with r a vaccine to prevent life threatening Candida i Furthermore, infections caused by strains and ..